JAK2

Where the papers sit

13 papers from the last 6 months study JAK2 directly · updated from PubMed 3 Oct 2026

• JAK2/STAT Signaling Therapies

  JAK2/STAT pathway modulation is being explored across inflammatory disease, infection, cancer, and tissue injury. Most studies test natural products or small molecules that suppress IL-6-driven STAT3 signaling and improve organ or inflammatory outcomes. One strategy instead activates JAK2 to protect against chemotherapy-induced myelosuppression, highlighting opposing therapeutic goals. Translation remains limited by heterogeneous preclinical models and sparse clinical validation.

  8 papers · 61.5%

• JAK Inhibition in GVHD

  JAK inhibition is moving into both prevention and treatment of graft-versus-host disease after haploidentical transplantation. Low-dose ruxolitinib is being tested to reduce incident GVHD, while baricitinib is directed at refractory chronic disease. Cumulative incidence, neutropenia, infection, and other transplantation outcomes remain central safety and efficacy measures. Evidence is still early, relying on multicentre and phase 1/2 clinical studies rather than definitive comparative trials.

  2 papers · 15.4%

• Others — Disease-Specific Clinical Assessment

  Clinical assessment spans topical treatment and delivery approaches for moderate atopic dermatitis alongside metabolomic diagnosis of polycythaemia vera. Ruxolitinib cream is being compared with systemic therapies using real-world severity and body-surface-area measures, while microneedles aim to improve transdermal sulforaphane delivery. Serum metabolomics pursues disease-specific signatures and diagnostic panels in polycythaemia vera. The cluster has no single biological or clinical direction beyond disease-focused evaluation.

  3 papers · 23.1%